This Inflammatory Bowel Disease Treatment market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $25.26 billion in 2024 to $27.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased prevalence of inflammatory bowel disease, growing demand for biologics and immunomodulators, advancements in treatment options, rising geriatric population, increased awareness aboutThe disease.
The inflammatory bowel disease treatment market size is expected to see rapid growth in the next few years. It will grow to $40.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing investment in research and development activities, growing demand for biosimilars, rising incidence of inflammatory bowel disease in emerging markets, growing demand for personalized medicine, integration of precision medicine in IBD treatment. Major trends in the forecast period include increasing number of product launches and approvals, personalized dosing and treatment plans in IBD management, use of telemedicine for remote monitoring of IBD patients, exploration of microbiome-based therapies for IBD, adoption of value-based care models in IBD treatment.
The significant increase in the prevalence of Crohn’s disease and ulcerative colitis is a key driver for the growth of the market for inflammatory bowel disease treatment. Crohn’s disease and ulcerative colitis, categorized as inflammatory bowel diseases (IBD), involve inflammation and ulcers in the digestive tracts. The growing incidence of these diseases is expected to elevate the demand for treatments that aim to reduce bowel inflammation and prevent medical complications. A March 2022 research publication from the United States National Library of Medicine indicates that approximately 1. 6 million Americans presently suffer from inflammatory bowel disease, with around 70,000 new cases diagnosed annually in the USA. Consequently, the increasing prevalence of Crohn's disease and ulcerative colitis is anticipated to propel the growth of the inflammatory bowel disease treatment market.
The rise in the geriatric population is forecasted to drive the growth of the inflammatory bowel disease treatment market in the future. The geriatric population, comprising individuals aged 65 and older, exhibits a higher susceptibility to inflammatory bowel diseases, resulting in an increased demand for treatments and therapies. This demographic shift is expected to contribute to the expansion of the inflammatory bowel disease treatment market. A report from the World Health Organization (WHO) in October 2022 highlights that by the year 2030, one in six people globally is expected to be 60 or older, and by 2050, there will be an estimated 2. 1 billion people worldwide aged 60 or older. Thus, the growth of the geriatric population is a significant factor propelling the inflammatory bowel disease treatment market.
Technological advancement is a significant trend gaining traction in the inflammatory bowel disease treatment market. Major companies in this sector are focusing on AI-driven registries to achieve a competitive advantage. For example, in May 2024, Verantos, a California-based real-world evidence (RWE) company, introduced the Inflammatory Bowel Disease Pragmatic Registry, which utilizes advanced artificial intelligence to produce high-quality real-world evidence (RWE) for ulcerative colitis and Crohn's disease. This registry is designed to aid in the development of effective therapies by offering a comprehensive dataset containing over 3 billion data points related to patient care. It enables biopharma researchers to gain in-depth insights into disease severity, treatment efficacy, and clinical outcomes by analyzing both structured and unstructured data from electronic health records.
Major companies in the inflammatory bowel disease treatment market are focusing on the development of innovative products targeting larger customer bases and increasing revenue. Treatments for moderate to severe active ulcerative colitis, involving medications and sometimes surgical interventions, are a key area of innovation. In October 2023, Eli Lilly and Company, a US-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), the first interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh targets the IL-23 pathway, effectively blocking inflammation associated with UC. The treatment regimen involves initial infusions followed by subcutaneous self-injections during the maintenance phase.
In March 2022, Pfizer, Inc., a U. S. -based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals, Inc., for $6. 7 billion. Through this acquisition, Pfizer aims to enhance its research capabilities in the Inflammation and Immunology therapeutic area, develop therapies for immuno-inflammatory diseases, and continue the clinical development of existing drug candidates. Arena Pharmaceuticals, Inc., is a U. S. -based biopharmaceutical company specializing in the development of novel treatments for various immuno-inflammatory conditions.
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.
North America was the largest region in the inflammatory bowel disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Treatment for inflammatory bowel disease involves the use of anti-inflammatory medications commonly employed for mild to moderate cases of ulcerative colitis. Aminosalicylates, including mesalamine (Delzicol, Rowasa, among others), balsalazide (Colazal), and olsalazine, serve as anti-inflammatories, with Dipentum being one of them.
The primary drug categories in the treatment of inflammatory bowel disease encompass aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and other options. Aminosalicylates, a specific class of drugs, are utilized to manage and prevent flare-ups in ulcerative colitis and Crohn's disease. The mechanism of action of aminosalicylates involves inhibiting the production of cyclo-oxygenase, prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and via injection, treatments for inflammatory bowel disease are administered for Crohn’s disease and ulcerative colitis. These medications are available through hospital pharmacies, retail pharmacies, and online pharmacies.
The inflammatory bowel disease treatment market research report is one of a series of new reports that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with an inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $25.26 billion in 2024 to $27.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased prevalence of inflammatory bowel disease, growing demand for biologics and immunomodulators, advancements in treatment options, rising geriatric population, increased awareness aboutThe disease.
The inflammatory bowel disease treatment market size is expected to see rapid growth in the next few years. It will grow to $40.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing investment in research and development activities, growing demand for biosimilars, rising incidence of inflammatory bowel disease in emerging markets, growing demand for personalized medicine, integration of precision medicine in IBD treatment. Major trends in the forecast period include increasing number of product launches and approvals, personalized dosing and treatment plans in IBD management, use of telemedicine for remote monitoring of IBD patients, exploration of microbiome-based therapies for IBD, adoption of value-based care models in IBD treatment.
The significant increase in the prevalence of Crohn’s disease and ulcerative colitis is a key driver for the growth of the market for inflammatory bowel disease treatment. Crohn’s disease and ulcerative colitis, categorized as inflammatory bowel diseases (IBD), involve inflammation and ulcers in the digestive tracts. The growing incidence of these diseases is expected to elevate the demand for treatments that aim to reduce bowel inflammation and prevent medical complications. A March 2022 research publication from the United States National Library of Medicine indicates that approximately 1. 6 million Americans presently suffer from inflammatory bowel disease, with around 70,000 new cases diagnosed annually in the USA. Consequently, the increasing prevalence of Crohn's disease and ulcerative colitis is anticipated to propel the growth of the inflammatory bowel disease treatment market.
The rise in the geriatric population is forecasted to drive the growth of the inflammatory bowel disease treatment market in the future. The geriatric population, comprising individuals aged 65 and older, exhibits a higher susceptibility to inflammatory bowel diseases, resulting in an increased demand for treatments and therapies. This demographic shift is expected to contribute to the expansion of the inflammatory bowel disease treatment market. A report from the World Health Organization (WHO) in October 2022 highlights that by the year 2030, one in six people globally is expected to be 60 or older, and by 2050, there will be an estimated 2. 1 billion people worldwide aged 60 or older. Thus, the growth of the geriatric population is a significant factor propelling the inflammatory bowel disease treatment market.
Technological advancement is a significant trend gaining traction in the inflammatory bowel disease treatment market. Major companies in this sector are focusing on AI-driven registries to achieve a competitive advantage. For example, in May 2024, Verantos, a California-based real-world evidence (RWE) company, introduced the Inflammatory Bowel Disease Pragmatic Registry, which utilizes advanced artificial intelligence to produce high-quality real-world evidence (RWE) for ulcerative colitis and Crohn's disease. This registry is designed to aid in the development of effective therapies by offering a comprehensive dataset containing over 3 billion data points related to patient care. It enables biopharma researchers to gain in-depth insights into disease severity, treatment efficacy, and clinical outcomes by analyzing both structured and unstructured data from electronic health records.
Major companies in the inflammatory bowel disease treatment market are focusing on the development of innovative products targeting larger customer bases and increasing revenue. Treatments for moderate to severe active ulcerative colitis, involving medications and sometimes surgical interventions, are a key area of innovation. In October 2023, Eli Lilly and Company, a US-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), the first interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh targets the IL-23 pathway, effectively blocking inflammation associated with UC. The treatment regimen involves initial infusions followed by subcutaneous self-injections during the maintenance phase.
In March 2022, Pfizer, Inc., a U. S. -based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals, Inc., for $6. 7 billion. Through this acquisition, Pfizer aims to enhance its research capabilities in the Inflammation and Immunology therapeutic area, develop therapies for immuno-inflammatory diseases, and continue the clinical development of existing drug candidates. Arena Pharmaceuticals, Inc., is a U. S. -based biopharmaceutical company specializing in the development of novel treatments for various immuno-inflammatory conditions.
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.
North America was the largest region in the inflammatory bowel disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Treatment for inflammatory bowel disease involves the use of anti-inflammatory medications commonly employed for mild to moderate cases of ulcerative colitis. Aminosalicylates, including mesalamine (Delzicol, Rowasa, among others), balsalazide (Colazal), and olsalazine, serve as anti-inflammatories, with Dipentum being one of them.
The primary drug categories in the treatment of inflammatory bowel disease encompass aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and other options. Aminosalicylates, a specific class of drugs, are utilized to manage and prevent flare-ups in ulcerative colitis and Crohn's disease. The mechanism of action of aminosalicylates involves inhibiting the production of cyclo-oxygenase, prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and via injection, treatments for inflammatory bowel disease are administered for Crohn’s disease and ulcerative colitis. These medications are available through hospital pharmacies, retail pharmacies, and online pharmacies.
The inflammatory bowel disease treatment market research report is one of a series of new reports that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with an inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Inflammatory Bowel Disease Treatment Market Characteristics3. Inflammatory Bowel Disease Treatment Market Trends and Strategies4. Inflammatory Bowel Disease Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Inflammatory Bowel Disease Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Inflammatory Bowel Disease Treatment Market34. Recent Developments in the Inflammatory Bowel Disease Treatment Market
5. Global Inflammatory Bowel Disease Treatment Growth Analysis and Strategic Analysis Framework
6. Inflammatory Bowel Disease Treatment Market Segmentation
7. Inflammatory Bowel Disease Treatment Market Regional and Country Analysis
8. Asia-Pacific Inflammatory Bowel Disease Treatment Market
9. China Inflammatory Bowel Disease Treatment Market
10. India Inflammatory Bowel Disease Treatment Market
11. Japan Inflammatory Bowel Disease Treatment Market
12. Australia Inflammatory Bowel Disease Treatment Market
13. Indonesia Inflammatory Bowel Disease Treatment Market
14. South Korea Inflammatory Bowel Disease Treatment Market
15. Western Europe Inflammatory Bowel Disease Treatment Market
16. UK Inflammatory Bowel Disease Treatment Market
17. Germany Inflammatory Bowel Disease Treatment Market
18. France Inflammatory Bowel Disease Treatment Market
19. Italy Inflammatory Bowel Disease Treatment Market
20. Spain Inflammatory Bowel Disease Treatment Market
21. Eastern Europe Inflammatory Bowel Disease Treatment Market
22. Russia Inflammatory Bowel Disease Treatment Market
23. North America Inflammatory Bowel Disease Treatment Market
24. USA Inflammatory Bowel Disease Treatment Market
25. Canada Inflammatory Bowel Disease Treatment Market
26. South America Inflammatory Bowel Disease Treatment Market
27. Brazil Inflammatory Bowel Disease Treatment Market
28. Middle East Inflammatory Bowel Disease Treatment Market
29. Africa Inflammatory Bowel Disease Treatment Market
30. Inflammatory Bowel Disease Treatment Market Competitive Landscape and Company Profiles
31. Inflammatory Bowel Disease Treatment Market Other Major and Innovative Companies
35. Inflammatory Bowel Disease Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Inflammatory Bowel Disease Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on inflammatory bowel disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for inflammatory bowel disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inflammatory bowel disease treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) Covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Aminosalicylates; Corticosteroids; TNF inhibitors; IL inhibitors; Anti-integrin; JAK inhibitors; Other Drug Classes2) By Type: Crohn's Disease; Ulcerative Colitis
3) By Route of Administration: Oral; Injectable
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine; Sulfasalazine; Balsalazide2) By Corticosteroids: Prednisone; Budesonide; Hydrocortisone
3) By TNF Inhibitors: Infliximab; Adalimumab; Certolizumab pegol
4) By IL Inhibitors: Ustekinumab; Guselkumab
5) By Anti-Integrin: Vedolizumab; Natalizumab
6) By JAK Inhibitors: Tofacitinib; Filgotinib
7) By Other Drug Classes: Antibiotics; Immunosuppressants; Other Novel Therapies
Key Companies Mentioned: AbbVie Inc.; Biogen Inc.; Johnson & Johnson; Amgen Inc.; Advanced Gastroenterology and Surgery Associates P. A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Inflammatory Bowel Disease Treatment market report include:- AbbVie Inc.
- Biogen Inc.
- Johnson & Johnson
- Amgen Inc.
- Advanced Gastroenterology and Surgery Associates P. A.
- Atlanta Gastroenterology Associates LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cedars-Sinai Medical Center
- Celgene Corporation
- Cleveland Clinic Foundation
- Digestive Disease Associates of Rockland P. C.
- Eli Lilly and Company
- Gastrointestinal Specialists Inc.
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Illinois Gastroenterology Group LLC
- The Johns Hopkins Hospital Inc.
- Massachusetts General Hospital
- Mayo Clinic
- Merck & Co. Inc.
- Mount Sinai Health System Inc.
- Novartis International AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Takeda Pharmaceutical Company Limited
- Texas Digestive Disease Consultants P. A.
- The Oregon Clinic - Gastroenterology West P. C.
- Salix Pharmaceuticals Inc.
- Vifor Pharma AG
- Zydus Pharmaceuticals (USA) Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 27.45 Billion |
| Forecasted Market Value ( USD | $ 40.27 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
